Single-cell RNA sequencing in cardiovascular development, disease and medicine
Advances in single-cell RNA sequencing (scRNA-seq) technologies in the past 10 years
have had a transformative effect on biomedical research, enabling the profiling and analysis …
have had a transformative effect on biomedical research, enabling the profiling and analysis …
Patient and disease–specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …
The tumor-suppressive human circular RNA CircITCH sponges miR-330-5p to ameliorate doxorubicin-induced cardiotoxicity through upregulating SIRT6, survivin …
D Han, Y Wang, Y Wang, X Dai, T Zhou… - Circulation …, 2020 - Am Heart Assoc
Rationale: Doxorubicin is one of the most potent antitumor agents available; however, its
clinical use is restricted because it poses a risk of severe cardiotoxicity. Previous work has …
clinical use is restricted because it poses a risk of severe cardiotoxicity. Previous work has …
Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy
M Prondzynski, MD Lemoine, ATL Zech… - EMBO Molecular …, 2019 - embopress.org
Hypertrophic cardiomyopathy (HCM) is a cardiac genetic disease accompanied by structural
and contractile alterations. We identified a rare c. 740C> T (p. T247M) mutation in ACTN 2 …
and contractile alterations. We identified a rare c. 740C> T (p. T247M) mutation in ACTN 2 …
Human engineered heart tissue models for disease modeling and drug discovery
The emergence of human induced pluripotent stem cells (hiPSCs) and efficient
differentiation of hiPSC-derived cardiomyocytes (hiPSC-CMs) induced from diseased …
differentiation of hiPSC-derived cardiomyocytes (hiPSC-CMs) induced from diseased …
Utility of iPSC-derived cells for disease modeling, drug development, and cell therapy
MW Nicholson, CY Ting, DZH Chan, YC Cheng… - Cells, 2022 - mdpi.com
The advent of induced pluripotent stem cells (iPSCs) has advanced our understanding of the
molecular mechanisms of human disease, drug discovery, and regenerative medicine. As …
molecular mechanisms of human disease, drug discovery, and regenerative medicine. As …
Platform-agnostic CellNet enables cross-study analysis of cell fate engineering protocols
Optimization of cell engineering protocols requires standard, comprehensive quality metrics.
We previously developed CellNet, a computational tool to quantitatively assess the …
We previously developed CellNet, a computational tool to quantitatively assess the …
Clinical trial in a dish: using patient-derived induced pluripotent stem cells to identify risks of drug-induced cardiotoxicity
Drug-induced cardiotoxicity is a significant clinical issue, with many drugs in the market
being labeled with warnings on cardiovascular adverse effects. Treatments are often …
being labeled with warnings on cardiovascular adverse effects. Treatments are often …
[HTML][HTML] Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue
PJM Wijnker, J van Der Velden - … et Biophysica Acta (BBA)-Molecular Basis …, 2020 - Elsevier
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and is
characterized by asymmetric left ventricular hypertrophy and diastolic dysfunction, and a …
characterized by asymmetric left ventricular hypertrophy and diastolic dysfunction, and a …
iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity
Many challenges remain in the preclinical evaluation, adjudication, and prioritization of
novel compounds in therapeutic discovery pipelines. These obstacles are evident by the …
novel compounds in therapeutic discovery pipelines. These obstacles are evident by the …